Gene: ADGRL2

23266
CIRL2|CL2|LEC1|LPHH1|LPHN2
adhesion G protein-coupled receptor L2
protein-coding
1p31.1
Ensembl:ENSG00000117114 MIM:607018 Vega:OTTHUMG00000009844 UniprotKB:O95490
NC_000001.11
SNP Mapped
OD|ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.239e-1 (AD)  2.904e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs1341260chr1:81898976 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs11163319chr1:81506757 (GRCh38.p7)A>Copioid dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0493251,2-dithiol-3-thione"1,2-dithiol-3-thione results in decreased expression of ADGRL2 mRNA"19162173
C0109142,4-diaminotoluene"2,4-diaminotoluene results in decreased expression of ADGRL2 mRNA"20713471
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of ADGRL2 mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRL2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of ADGRL2 mRNA21420995
D000082AcetaminophenAcetaminophen affects the expression of ADGRL2 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of ADGRL2 mRNA19770486
C020763alpha-latrotoxinADGRL2 protein results in increased susceptibility to alpha-latrotoxin10026162
C020763alpha-latrotoxinalpha-latrotoxin binds to ADGRL2 protein10026162
C020763alpha-latrotoxin[alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium10026162
C015001arsenitearsenite results in decreased expression of ADGRL2 mRNA23974009
C547126AZM551248AZM551248 results in decreased expression of ADGRL2 mRNA22323515
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of ADGRL2 mRNA26377693
D019324beta-NaphthoflavoneAHR protein affects the reaction [beta-Naphthoflavone results in decreased expression of ADGRL2 mRNA]22234961
D019324beta-Naphthoflavonebeta-Naphthoflavone results in decreased expression of ADGRL2 mRNA22234961
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ADGRL2 mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ADGRL2 mRNA22610609
D004958Estradiol[Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA20660070
C006780bisphenol Abisphenol A results in increased expression of ADGRL2 mRNA29275510
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA28628672
C006780bisphenol Abisphenol A affects the expression of ADGRL2 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of ADGRL2 mRNA12075121
C038599black widow spider venomADGRL2 protein results in increased susceptibility to black widow spider venom10026162
C038599black widow spider venomblack widow spider venom binds to ADGRL2 protein10026162
C038599black widow spider venom[black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium10026162
C018475butyraldehydebutyraldehyde results in decreased expression of ADGRL2 mRNA26079696
D002118Calcium[alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium10026162
D002118Calcium[black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium10026162
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene20938992
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL220938992
D002857ChromiumChromium results in decreased expression of ADGRL2 mRNA21437242
D003300Copper[ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA15467011
D003471CuprizoneCuprizone results in decreased expression of ADGRL2 mRNA26577399
D016572CyclosporineCyclosporine results in decreased expression of ADGRL2 mRNA20106945|2556210
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA28628672
D003907DexamethasoneDexamethasone results in decreased expression of ADGRL2 mRNA14618091
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ADGRL2 mRNA17361019|2126653
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ADGRL2 mRNA21266533
D004041Dietary FatsDietary Fats results in increased expression of ADGRL2 mRNA18042831
D004041Dietary FatsDietary Fats results in decreased expression of ADGRL2 mRNA21852083
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ADGRL2 mRNA"22485181
D000431EthanolEthanol results in increased expression of ADGRL2 mRNA15353170
D005472FluorouracilADGRL2 protein affects the susceptibility to Fluorouracil16217747
C061365flusilazoleflusilazole affects the expression of ADGRL2 mRNA21195148
D005485FlutamideFlutamide results in decreased expression of ADGRL2 mRNA24136188|2479361
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene20938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL220938992
D004397FonofosFonofos results in increased methylation of ADGRL2 promoter22847954
C039281furanfuran results in increased methylation of ADGRL2 gene22079235
C409722hexaconazolehexaconazole affects the expression of ADGRL2 mRNA21195148
D017313FenretinideFenretinide results in increased expression of ADGRL2 mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA28628672
C098607JP8 aviation fuelJP8 aviation fuel results in decreased expression of ADGRL2 mRNA15618438
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL220938992
D008727MethotrexateADGRL2 protein affects the susceptibility to Methotrexate16217747
D009151Mustard GasMustard Gas affects the expression of ADGRL2 mRNA15651846
C051752nefazodonenefazodone results in decreased expression of ADGRL2 mRNA24136188
C012655nimesulidenimesulide results in decreased expression of ADGRL2 mRNA24136188
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA25729387
D000073878Palm OilPalm Oil results in increased expression of ADGRL2 mRNA18042831
D010278ParathionParathion results in increased methylation of ADGRL2 promoter22847954
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of ADGRL2 mRNA19710929
C006253pirinixic acidpirinixic acid results in decreased expression of ADGRL2 mRNA19162173
D010936Plant ExtractsPlant Extracts results in decreased expression of ADGRL2 mRNA23557933
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of ADGRL2 mRNA22714537
D011374Progesterone[Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA20660070
D011441PropylthiouracilPropylthiouracil results in increased expression of ADGRL2 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of ADGRL2 mRNA21632981
C041711St. Thomas' Hospital cardioplegic solutionSt. Thomas' Hospital cardioplegic solution results in decreased expression of ADGRL2 mRNA16214533
C012568terbufosterbufos results in increased methylation of ADGRL2 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ADGRL2 mRNA20106945|2163298
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of ADGRL2 mRNA25975270
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA25729387
D019772TopotecanTopotecan results in increased expression of ADGRL2 mRNA25729387
C032910triadimefontriadimefon affects the expression of ADGRL2 mRNA21195148
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRL2 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of ADGRL2 mRNA24383497|2627250
D014638VanadatesVanadates results in increased expression of ADGRL2 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ADGRL2 gene25560391
C111237vorinostatvorinostat results in increased expression of ADGRL2 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001965G-protein alpha-subunit binding-IBA21873635  
GO:0004930G-protein coupled receptor activity-IBA21873635  
GO:0004930G-protein coupled receptor activity-IEA-  
GO:0016524latrotoxin receptor activity-NAS10030676  
GO:0030246carbohydrate binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007166cell surface receptor signaling pathway-IEA-  
GO:0007186G-protein coupled receptor signaling pathway-NAS10030676  
GO:0007420brain development-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0016021integral component of membrane-NAS10030676  
GO:0043005neuron projection-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal